Overview of the Research Goals of the Yarema Laboratory


1. Yarema, K.J., Mahal, L.K., Bruehl, R.E., Rodriguez, E.C. & Bertozzi, C.R. Metabolic delivery of ketone groups to sialic acid residues. Application to cell surface glycoform engineering. J. Biol. Chem. 273 , 31168-31179 (1998).

2. Lemieux, G.A., Yarema, K.J., Jacobs, C.L. & Bertozzi, C.R. Exploiting differences in sialoside expression for selective targeting of MRI contrast reagents. J. Am. Chem. Soc. 121 , 4278-4279 (1999).

3. Mahal, L.K., Yarema, K.J. & Bertozzi, C.R. Engineering chemical reactivity on cell surfaces through oligosaccharide biosynthesis. Science 276 , 1125-1128 (1997).

4. Mahal, L.K., Yarema, K.J., Lemieux, G.A. & Bertozzi, C.R. in Sialobiology and Other Novel Forms of Glycosylation. (eds. Y. Inoue, Y.C. Lee & F.A. Troy II) 273-280 (Gakushin Publishing Company, Osaka, Japan; 1999).

5. Keppler, O.T., Horstkorte, R., Pawlita, M., Schmidt, C. & Reutter, W. Biochemical engineering of the N -acyl side chain of sialic acid: biological implications. Glycobiology 11 , 11R-18R (2001).

6. Jones, M.B., Teng, H., Rhee, J.K., Baskaran, G., Lahar, N. & Yarema, K.J. Characterization of the cellular uptake and metabolic conversion of acetylated N -acetylmannosamine (ManNAc) analogues to sialic acids. Biotechnol. Bioeng. 85 , 394-405 (2004).

7. Kim, E.J., Jones, M.B., Rhee, J.K., Sampathkumar, S.-G. & Yarema, K.J. Establishment of N -acetylmannosamine (ManNAc) analogue-resistant cell lines as improved hosts for sialic acid engineering applications. Biotechnol. Prog. 20 , 1674-1682 (2004).

8. Kim, E.J., Sampathkumar, S.-G., Jones, M.B., Rhee, J.K., Baskaran, G. & Yarema, K.J. Characterization of the metabolic flux and apoptotic effects of O -hydroxyl- and N -acetylmannosamine (ManNAc) analogs in Jurkat (human T-lymphoma-derived) cells. J. Biol. Chem. 279 , 18342-18352 (2004).

9. Sampathkumar, S.-G., Jones, M.B., Meledeo, M.A., Campbell, C.T., Choi, S.S., Hida, K., Gomutputra, P., Sheh, A., Gilmartin, T., Head, S.R. & Yarema, K.J. Targeting glycosylation pathways and the cell cycle: sugar- dependent activity of butyrate-carbohydrate cancer prodrugs. Chem. Biol. 13 , 1265-1275 (2006).

10. Sampathkumar, S.-G., Campbell, C.T., Weier, C. & Yarema, K.J. Short-chain fatty acid-hexosamine cancer prodrugs: The sugar matters! Drugs Future 31 , 1099-1116 (2006).

11. Campbell, C.T., Aich, U., Weier, C.A., Wang, J.J., Choi, S.S., Wen, M.M., Maisel, K., Sampathkumar, S.-G. & Yarema, K.J. Targeting pro-invasive oncogenes with short chain fatty acid-hexosamine analogs inhibits the mobility of metastatic MDA-MB-231 breast cancer cell. J. Med. Chem. 51 , 8135–8147 (2008).

12. Aich, U., Campbell, C.T., Elmouelhi, N., Weier, C.A., Sampathkumar, S.-G., Choi, S.S. & Yarema, K.J. Regioisomeric SCFA attachment to hexosamines separates metabolic flux from cytotoxcity and MUC1 suppression. ACS Chem. Biol. 3 , 230-240 (2008).

13. Lavis, L.D. Ester bonds in prodrugs. ACS Chem. Biol. 3 , 203-206 (2008).